Detection of cancer at an early stage when it is still localized improves patient response to
medical interventions for most cancer types. The success of screening tools such as cervical …

BACKGROUND Characterizing ovarian pathology is fundamental to optimizing
management in both pre-and post-menopausal women. Inappropriate referral to oncology …

Objective To present an update of the European Group on Tumor Markers guidelines for
serum markers in epithelial ovarian cancer. Methods Systematic literature survey from 2008 …

Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in
fact,> 80% of cases are diagnosed as advanced-stage disease associated with a high …

Cancer is the second most common cause of death in developed countries with
approximately 14 million newly diagnosed individuals and over 6 million cancer‐related …

Patients with high-grade serous ovarian carcinoma (HGSC) exhibit poor 5-year survival
rates, which may be significantly improved by early-stage detection. The US Food and Drug …

Evidence of a mortality benefit continues to elude ovarian cancer (OC) screening. Data from
the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial which used a …

Background: Exosomes are extracellular microvesicles that are released by most cells and
widely distributed in various body fluids. Malignant cells secrete large amounts of exosomes …

Ovarian cancer is usually detected at a late stage and the overall 5-year survival is only 30–
40%. Additional means for early detection and improved diagnosis are acutely needed. To …

Objective To validate, in a multicenter clinical trial, the performance of biomarkers and
algorithms for differential diagnosis in a population of women diagnosed with an unknown …